Trial Profile
A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 29 Dec 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide
- Indications Connective tissue disorders; Dermatomyositis; Interstitial lung diseases; Polymyositis; Systemic scleroderma
- Focus Therapeutic Use
- Acronyms RECITAL
- 14 Nov 2022 Results of subgroup analysis of this trial presented at the ACR Convergence 2022
- 06 Oct 2021 Status changed from discontinued to completed.
- 08 Mar 2021 Status changed from active, no longer recruiting to discontinued.